🔗 Share this article

As the US undertakes historic adjustments to its immunization schedules, a particular individual appears in a surprising turn: Dr. Tracy Beth Høeg, an American of Danish descent sports medicine doctor and epidemiologist who first made her name by expressing skepticism about Covid shots throughout the global health crisis and has focused upon alleged fatalities after COVID-19 vaccination in her short position at the FDA.

Planned Shifts to Childhood Immunization Program

Health officials were set to reveal sweeping revisions to the pediatric vaccine schedule in December, bringing the US with the Danish vaccine program, sources say – a significant shift that would place the US out of alignment with many the global community with no evidence for public health gain. The announcement has been delayed until the next year.

Instead of the director of the vaccine center, Høeg is scheduled to speak at the gathering. She was just designated interim head of the FDA’s CDER, the fifth individual to head the center this calendar year.

A New Direction at the Regulatory Body

This interim role may indicate a strengthened alliance between the pharmaceutical and vaccine branches as Dr. Høeg and Dr. Prasad strengthen their influence at the agency – and it points to a increased emphasis upon reevaluating already-approved vaccines at the FDA.

Høeg has repeatedly called for discontinuing specific childhood shot schedules in the US so as to align more in line with Denmark's approach, a country with comprehensive healthcare and a population roughly the size of the state of Wisconsin.

In her initial comments, she has persisted in emphasizing on vaccination policy – usually the responsibility of Dr. Prasad, chief of the FDA’s CBER – rather than medication approval.

Concerns Over Background

Dr. Høeg has no obvious experience in drug development, regulation or management, which has been standard for past heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the agency head and CBER since spring.

“She appears not to have the requisite experience” for leading the drug-regulation department, remarked Jonathan Howard. “She has not conducted a scientific study. She is not versed in managing a major agency. She is not an expert in pharmaceutical oversight.”

Previous commissioners of the center would “be deeply familiar with legal statutes and the research of medication creation”, commented Dr. Janet Woodcock. “Objectively, she has not acquired the type of experience that former directors who headed the center have had.”

CDER has an immense workload at the agency, she stated.

“The public just focuses on the novel medication approvals, but the off-patent medication office authorizes thousands of generic drugs. There’s a biosimilars program, non-prescription drug unit and other areas, and every single one need to be supervised,” Woodcock said. “The thing you neglect, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a significant management component to the position, which supervises over 5,000 personnel. “It’s a massive administrative position, if you perform it correctly,” Woodcock concluded.

Response and Contentious Policies

Regarding questions about Høeg’s qualifications and whether this assignment indicates increased cooperation among FDA leaders on immunizations, a representative responded that the “questions rely on inaccurate premises”.

“This background is consistent with the responsibilities of her position,” the official explained, citing the months Dr. Høeg spent counseling the agency head on “medication safety and approval science, including computerized risk analysis and vaccine surveillance”.

In her interim role, Dr. Høeg takes over the agency head's recently launched expedited review system, a disputed one-day medication authorization process that reportedly concerned her predecessors. “By what process are these medications being picked for this expedited pathway? Who takes the choices?” Howard asked. “There’s a lot of confidentiality occurring at the agency right now.”

Overall, he said, “the Food and Drug Administration appears to be shifting towards laxer oversight of all drugs, aside from vaccines.”

Documented Track Record on Immunizations

Regarding vaccines, Høeg has a clearer, if concerning, past, Howard said. She published a research paper using unverified public submissions to estimate the frequency of heart inflammation after COVID-19 immunization. She advised the state of Florida surgeon general Dr. Joseph Ladapo, who reportedly have changed statistics to suggest COVID-19 vaccinations are more dangerous than they are.

Included in her “desired changes” for the incoming federal leadership featured revising guidelines for novel immunizations and halting “optional” immunizations, she stated after the election on a audio program. At the FDA, Dr. Høeg has reportedly proposed barring teenage boys from receiving Covid vaccines.

“She’s an all-around ideologue who starts off with her preconceived notions and works backwards to retrofit the evidence in a extremely misleading, untruthful way,” Dr. Howard stated.

Taking Control and a “Push for Payback”

Dr. Høeg became part of other contrarians, {like|